Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Senescence profiling and biomarker identification in cell product based on adipose tissue-derived mesenchymal stromal cells.

Johansen EM., Hoeeg C., Søndergaard RH., Højgaard LD., Lethager LL., Bangsgaard S.

Laboratory Study on Immune Modulation, published in Stem Cells Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Stem Cells Transl Med (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41791726
PMCID
PMC12965767
DOI
10.1093/stcltm/szag011

Abstract (original English)

Background/aim Adipose tissue-derived mesenchymal stromal cells (ASC) are used in advanced therapy medicinal products due to their regenerative and immunomodulatory properties. Increasing the number of dosages derived from each donor product is essential to reduce variability and improve scalability of cell therapy. However, extended in vitro expansion may induce cellular senescence, potentially compromising therapeutic efficacy. This study aimed to assess the remaining proliferative potential of a cryopreserved ASC product and identify robust transcriptomic -biomarkers of senescence. Methods ASC from five donors were cultured until replicative senescence or passage 10. Morphology, growth kinetics, and confluence were monitored. Bulk RNA sequencing was performed on samples from passage 1, 3, 6, and final passage. Principal component analysis, differential expression, gene set variation analysis, and variance partitioning were used to characterize transcriptional changes and identify biomarkers. Results ASC maintained stable proliferation and morphology for at least three passages post-thaw. Major transcriptional shifts occurred between passage 3 and later passages. Senescence-associated gene enrichment increased progressively, with donor-specific variation evident at intermediate passages. Forty biomarkers (20 upregulated, 20 downregulated) were identified with expression chang

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsHumansCellular SenescenceAdipose TissueBiomarkersCell ProliferationCells, CulturedCryopreservation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research